BiotechTube
Corsair Pharma

Corsair Pharma

Cambridge, United States· Est.
corsairpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Corsair Pharma is a private, pre-revenue biotech founded in 2018, headquartered in Cambridge, USA, developing an improved transdermal therapy for pulmonary arterial hypertension (PAH). Its lead candidate is a proprietary patch delivering a prodrug of treprostinil, designed to offer consistent drug levels without the burdens and side effects of current infusion pumps. With a strategic partnership with United Therapeutics and plans to initiate a Phase 1 trial in late 2024, Corsair is targeting a significant unmet need in an orphan disease market dominated by complex, invasive therapies.

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension

Technology Platform

Proprietary transdermal patch designed to deliver small molecule prodrugs. The platform involves a patch for controlled transdermal delivery and prodrug chemistry for rapid conversion to the active drug in the liver, aiming to provide consistent systemic drug levels and improved local tolerability.

Opportunities

The primary opportunity is addressing the significant unmet need for a convenient, well-tolerated prostacyclin therapy in PAH, a multi-billion dollar orphan disease market.
A successful transdermal patch could capture market share from invasive infusion therapies and less convenient oral/inhaled options, potentially becoming a new standard of care.
The strategic partnership with market leader United Therapeutics provides a clear potential path to commercialization and validates the program's strategic value.

Risk Factors

Key risks include clinical development risk, particularly in demonstrating bioequivalent drug levels and safety of the novel prodrug; technical risk in achieving consistent transdermal delivery; and competitive risk from other companies developing improved PAH therapies.
As a pre-revenue private company, Corsair also faces financial risk and dependence on raising capital to fund costly clinical trials.

Competitive Landscape

Corsair competes in the PAH prostacyclin market, dominated by United Therapeutics' products (Remodulin IV/SC, Tyvaso inhaled, Orenitram oral). Competition includes other companies developing improved delivery methods for prostacyclins and drugs targeting other pathways (endothelin, nitric oxide). Corsair's differentiation is its non-invasive, pain-avoiding transdermal patch designed for consistent drug levels, positioning it as a potential best-in-class delivery option for treprostinil.

More companies in Small Molecule Drugs →More companies in United States →